Allergan, Inc.

Wha Bin Im

Ken Chow

Dennis E Van Epps

Guang-Liang Jiang

Ling Li

Janet A Takeuchi

Liming Wang

Wenkui Ken Fang

Evelyn G Corpuz

Gregory H Altman

Jingsong Chen

Rebecca L Horan

Adam L Collette

Michael E Garst

Robert M Burk

David W Old

Santosh C Sinha

Smita S Bhat

Daniel W Gil

Larry Allen Wheeler

Danny Thang Dinh

Scott M Whitcup

Richard S Graham

Vinh X Ngo

Karen M Kedzie

Frederick C Beddingfield

Mu-Lan Lee

Guan-Liang Jiang

Guang L Jiang

Described herein are ester prodrugs of gamma-lactam compounds of Formula (I): or pharmaceutically acceptable salt thereof, and methods of use of such compounds for the treatment of ocular diseases including, among other things, glaucoma and macular degeneration. 

Ester prodrugs of gamma-lactams and their use

Disclosed herein are compounds according to Formulas 1-12, compositions comprising these compounds, and methods of lowering intraocular pressure (IOP) or causing hair growth, and methods of using the same. 

Quaternary ammonium alkyl esters as stable prodrugs

The present invention relates to bicyclic 1,3,4-oxadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.

Bicyclic 1,3,4-oxadiazole derivatives as sphingosine-1-phosphate receptors' modulators

The specification discloses compositions and methods for treating a soft tissue defect of an individual.

Methods of treating soft tissue defects

The present invention relates to pyrazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.

Pyrazole derivatives as sphingosine 1-phosphate (S1P) receptor modulators

Compositions and methods for treating glaucoma are provided. In particular hydrophilic ester prodrugs and their use to reduce central corneal thickening is provided.

Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes

The present invention relates to novel diphenylethyne derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.

Modulators of S1P receptors

The present invention relates to pyrazole azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.

Pyrazole azetidine derivatives as sphingosine 1-phosphate (S1P) receptor modulators

Compositions and soft tissue replacement methods

The present invention relates to substituted dihydropyrazoles, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.

Substituted dihydropyrazoles as sphingosine receptor modulators

The present invention relates to substituted pyrazole azetidines, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.

Substituted pyrazole azetidines as sphingosine receptor modulators

The present invention relates to novel bicyclic methyl amine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.

Bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators

The invention relates to compositions comprising a silk fibroin material, adipose tissue and a compound of the structure where Xand Xare independently CH or N; Xis NH, O or S; Xand Xare independently CH or N; Ris an optionally substituted aryl or optionally substituted heteroaryl and Ris Calkyl, optionally substituted aryl or optionally substituted heteroaryl. The composition is administered to a site of a soft tissue condition including those of breast tissue. The silk fibroin material can be in the form of a silk hydrogel, a silk film, a silk scaffold, a silk sheet, a silk porous material or a silk fiber. The silk fibroin material can be substantially sericin free.

The invention relates to compositions comprising adipose tissue, a silk fibroin material and a compound of the structure The composition is administered to a site of a soft tissue condition including those of breast tissue. The silk fibroin material can be in the form of a silk hydrogel, a silk film, a silk scaffold, a silk sheet, a silk porous material, a silk fiber or a combination of those materials. The silk material may be substantially sericin free.

Growing community of inventors

Irvine, CA, United States of America

Wha Bin Im